Clinical trial · Observational
Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)
The Second Affiliated Hospital of Hainan Medical University
NCT06531681CI-TRIAL-00085970recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
| Overall Response Rate | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| Radiation Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MR-Linac | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- overall response rate
- timeFrame
- 3months， 6months，12months，24months，36months，60months
- description
- The proportion of patients whose tumor volume reduction reached the predetermined value and maintained the minimum time limit requirement was the sum of CR (Complete Response) and PR (Partial Response) proportions.
Secondary outcomes (8)
- measure
- Progression-Free Survival
- timeFrame
- 3months， 6months，12months，24months，36months，60months
- description
- The time from the start of treatment until objective tumor Progression or patient all-cause death
- measure
- Disease Control Rate
- timeFrame
- 3months， 6months，12months，24months，36months，60months
- description
- The percentage of patients whose cancer shrinks or remains stable over time
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients are undergoing or have undergone imaging or treatment at the MR linac; * Age 18-75 years, male or female; * ECOG score 0-2, life expectancy \> 6 months; * Patients provide written informed consent. Exclusion Criteria: * Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI; * The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy; * Acute inflammatory disease requiring systemic therapy; * The presence of active infectious disease; * Pregnant women, nursing mothers, and patients planning to have children during the study period.
References
Publications (0)
Data not yet available
No reference posted for this study.